UNICA IRIS Institutional Research Information System

CHESSA, LUCHINO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 216.585
NA - Nord America 11.129
AS - Asia 5.198
SA - Sud America 1.126
AF - Africa 143
OC - Oceania 31
Continente sconosciuto - Info sul continente non disponibili 7
Totale 234.219
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 212.013
US - Stati Uniti d'America 10.920
SG - Singapore 2.253
CN - Cina 1.846
NL - Olanda 1.145
BR - Brasile 911
SE - Svezia 823
UA - Ucraina 735
DE - Germania 551
GB - Regno Unito 426
VN - Vietnam 381
FI - Finlandia 347
FR - Francia 158
KR - Corea 136
CA - Canada 128
HK - Hong Kong 103
IN - India 95
AR - Argentina 81
AT - Austria 78
MX - Messico 53
ZA - Sudafrica 48
RU - Federazione Russa 46
BD - Bangladesh 43
ID - Indonesia 42
PL - Polonia 42
TR - Turchia 39
EC - Ecuador 35
JP - Giappone 35
MA - Marocco 35
ES - Italia 34
IE - Irlanda 33
CO - Colombia 30
AU - Australia 28
PK - Pakistan 26
IQ - Iraq 23
VE - Venezuela 23
CZ - Repubblica Ceca 22
IR - Iran 20
BE - Belgio 19
LT - Lituania 16
TW - Taiwan 16
IL - Israele 15
CL - Cile 14
EG - Egitto 14
MY - Malesia 14
SA - Arabia Saudita 14
KE - Kenya 13
PY - Paraguay 12
UZ - Uzbekistan 12
CH - Svizzera 11
DK - Danimarca 11
PE - Perù 10
RO - Romania 10
AE - Emirati Arabi Uniti 9
AZ - Azerbaigian 9
KZ - Kazakistan 9
TH - Thailandia 8
JO - Giordania 7
PT - Portogallo 7
BG - Bulgaria 6
DZ - Algeria 6
RS - Serbia 6
TT - Trinidad e Tobago 6
UY - Uruguay 6
GR - Grecia 5
MD - Moldavia 5
MK - Macedonia 5
OM - Oman 5
PA - Panama 5
TN - Tunisia 5
AL - Albania 4
BH - Bahrain 4
HR - Croazia 4
KG - Kirghizistan 4
LB - Libano 4
LV - Lettonia 4
NO - Norvegia 4
NP - Nepal 4
PH - Filippine 4
UG - Uganda 4
AO - Angola 3
AP - ???statistics.table.value.countryCode.AP??? 3
BO - Bolivia 3
CR - Costa Rica 3
EU - Europa 3
HU - Ungheria 3
JM - Giamaica 3
KW - Kuwait 3
LC - Santa Lucia 3
LU - Lussemburgo 3
NG - Nigeria 3
NZ - Nuova Zelanda 3
SI - Slovenia 3
BN - Brunei Darussalam 2
BY - Bielorussia 2
CG - Congo 2
CY - Cipro 2
DO - Repubblica Dominicana 2
HN - Honduras 2
LA - Repubblica Popolare Democratica del Laos 2
Totale 234.190
Salva come PNG Salva come JPEG
Città #
Cagliari 205.381
Uta 5.009
Dallas 1.151
Amsterdam 1.082
Ashburn 977
Fairfield 915
Singapore 877
Woodbridge 783
Chandler 734
Boardman 649
Houston 604
Nyköping 520
Ann Arbor 408
Jacksonville 393
Beijing 370
Seattle 354
Wilmington 353
Cambridge 294
Los Angeles 203
Boston 201
Hefei 195
Dearborn 192
Helsinki 183
Munich 177
New York 171
Santa Clara 164
Shanghai 153
Nanjing 150
Rome 138
Seoul 123
Buffalo 114
Ho Chi Minh City 113
Milan 106
São Paulo 95
Hong Kong 94
San Diego 82
Dong Ket 78
Redwood City 73
The Dalles 70
Hanoi 58
Mansfield 57
Guangzhou 54
Nuremberg 52
Nanchang 50
London 49
Turku 48
Vienna 47
Redondo Beach 46
Toronto 45
Frankfurt am Main 42
Tianjin 40
Jiaxing 38
Oxford 38
Hebei 37
Shenyang 37
Changsha 36
Chicago 36
Norwalk 35
Warsaw 34
Atlanta 32
Council Bluffs 32
Montreal 32
Rio de Janeiro 31
Paris 29
Tokyo 29
Washington 27
Brooklyn 26
Sassari 26
Casablanca 23
Dublin 23
Johannesburg 22
Mountain View 22
Orange 22
San Mateo 22
Denver 21
Birmingham 20
Düsseldorf 20
Nottingham 20
Verona 20
Belo Horizonte 19
Mexico City 19
Stockholm 19
Lappeenranta 18
Brussels 17
Chennai 17
Jinan 17
Naples 17
Orem 17
Wuhan 16
Ferrara 15
Kunming 15
Bari 14
Curitiba 14
Da Nang 14
Manchester 14
Bogotá 13
Brasília 13
Florence 13
Jakarta 13
Phoenix 13
Totale 225.434
Salva come PNG Salva come JPEG
Nome #
Comparing the responses of countries and National Health Systems to the COVID-19 pandemic: a critical analysis with a case-report series 20.756
Exploring the Role of Killer Cell Immunoglobulin-Like Receptors and Their HLA Class I Ligands in Autoimmune Hepatitis 4.510
Absence of activating killer immunoglobulin-like receptor genes combined with hepatitis C viral genotype is predictive of hepatocellular carcinoma 3.347
Gastrointestinal Coronavirus disease 2019: epidemiology, clinical features, pathogenesis, prevention, and management 3.227
Killer cell immunoglobulin-like receptors and their HLA class I ligands in autoimmune hepatitis: a possible pathogenetic role ? 3.106
HLA-G is highly expressed by plasma cells infiltrating hepatic tissue of patients affected by autoimmune hepatitis 3.101
Altered profile of salivary proteins in patients with Autoimmune Hepatitis 2.908
Bone mass preservation with high-dose cholecalciferol and dietary calcium in HIV patients following antiretroviral therapy. Is it possible? 2.886
Role of interferon lambda 4 and ALT levels in optimising treatment of HCV for patients with low-stage fibrosis 2.800
Impact of direct-acting antiviral drugs for chronic hepatitis C on mood: Preliminary results from a longitudinal study 2.720
Impact of natural killer (NK) cells receptors gene haplotypes on the development of hepatocarcinoma in cirrhotic patients 2.670
Hippocampal axis dysfunction evaluation by Rey-Osterrieth Complex figure test (RCFT) should be included in minimal hepatic encephalopathy (MHE) assessment 2.606
IMPACT OF KILLER-CELL IMMUNOGLOBULIN-LIKE RECEPTORS ON PROGRESSION OF HEPATOCELLULAR CARCINOMA 2.543
Combination of IFNL4 polymorphisms and ALT reduction at 4 week of treatment with PEG IFN and Ribavirin is a new selection tool to optimize antiviral treatment allocation in HCV patients with low stage fibrosis 2.522
Behavior of bone mass in long-term HAART patients 2.468
Association of chronic hepatitis C with recurrent brief depression 2.435
FATTORI IMPLICATI NELLA STORIA NATURALE DELL'INFEZIONE DA VIRUS DELTA:IL RUOLO DEGLI INTERFERONI 2.410
Role of natural killercells receptors on the development and progression of hepatocellularcarcinoma 2.380
INFLUENZA DEI POLIMORFISMI DELL’INTERFERONE LAMBDA NELLA STORIA NATURALE DELLA INFEZIONE CRONICA DA HBV: COINCIDENZA O REALTÀ? 2.275
Role of HLA-G in autmoimmune hepatitis 2.262
Entropy of human leukocyte antigen and killer-cell immunoglobulin-like receptor systems in immune-mediated disorders: A pilot study on multiple sclerosis 2.163
Dynamics of TT virus infection in a cohort of HCV-infected patients achieving sustained virologic responce after treatment with direct-acting antivirals 2.130
Safety and efficacy of direct-acting antivirals in transfusion-dependent thalassemic patients with chronic hepatitis C 2.121
Evaluation of mild cognitive dysfunction by Montreal Cognitive Assessment test in patients with chronic HCV infection treated with direct antiviral agents 1.980
Human Leukocyte Antigen Complex and Other Immunogenetic and Clinical Factors Influence Susceptibility or Protection to SARS-CoV-2 Infection and Severity of the Disease Course. The Sardinian Experience 1.968
A multivariate approach for the brain impairment in patients with liver cirrhosi 1.965
La neopterina uraria come marker di attività immunologica nelle malattie infiammatorie croniche dell’intestino 1.920
Efficacy and tolerability of treatment with the new direct acting antivirals (DAAs) in thalassemic patients with chronic Hepatitis 1.889
Is the Inversion in the Trend of the Lethality of the COVID-19 in the Two Hemispheres due to the Difference in Seasons and Weather? 1.871
Add-on peginterferon alfa-2a to nucleos(t)ide analogue therapy for Caucasian patients with hepatitis B 'e' antigen-negative chronic hepatitis B genotype D 1.806
Evaluation of mild cognitive dysfunction by Montreal Cognitive Assessment test in co-infected HIV-HCV patients treated with the new direct acting antivirals (DAAs) 1.745
null 1.742
Long-latency potential study in minimal hepatic hencephalopaty 1.724
null 1.710
Treatment of chronic hepatitis C in patients with glucose-6-phosphate dehydrogenase deficiency: is ribavirin harmful? 1.685
The climate in the European Union and the enlarged European Region is a determinant of the COVID-19 case fatality ratio 1.667
null 1.666
The Effect of Exposure to SARS-CoV-2 Vaccination and Infection on Humoral and Cellular Immunity in a Cohort of Patients with Immune-Mediated Diseases: A Pilot Study 1.629
SAFETY AND EFFICACY OF PEG-IFN alpha 2a AND RIBAVIRIN FOR TREATMENT OF HEPATITIS C IN SARDINIAN ADULT PATIENTS WITH THALASSEMIA MAJOR: A SINGLE CENTRE REAL LIFE EXPERIENCE 1.626
Randomised study comparing 48 and 96 weeks peginterferon α-2a therapy in genotype D HBeAg-negative chronic hepatitis B 1.614
null 1.610
Multidimensional geriatric assessment in elderly HIV patients 1.608
Evolution of the viral quasispecies tracked by sequence analysis during interferon treatment of chronic hepatitis C. 1.580
Awareness, discussion and non-prescribed use of HIV pre-exposure prophylaxis among persons living with HIV/AIDS in Italy: a Nationwide, cross-sectional study among patients on antiretrovirals and their treating HIV physicians 1.518
Economic Consequences of Investing in Anti-HCV Antiviral Treatment from the Italian NHS Perspective: A Real-World-Based Analysis of PITER Data 1.513
EVALUATION OF MILD COGNITIVE DYSFUNCTION BY MONTREAL COGNITIVE ASSESSMENT TEST IN PATIENTS WITH CHRONIC HCV INFECTION 1.502
HepaDisk – A new quality of life questionnaire for HCV patients 1.496
The COVID-19 incidence in Italian regions correlates with low temperature, mobility and PM10 pollution but lethality only with low temperature 1.494
Orthotopic liver transplantation in neurological Wilson desease: case report 1.472
null 1.424
Profiling the risk of hepatocellular carcinoma after long-term HCV eradication in patients with liver cirrhosis in the PITER cohort 1.414
Natural killer-cell immunoglobulin-like receptors trigger differences in immune response to SARS-CoV-2 infection 1.400
Individualized long-term treatment of chronic hepatitis C with interferon alpha (IFN alpha)-2a. 1.386
Real-life use of elbasvir/grazoprevir in adults and elderly patients: a prospective evaluation of comedications used in the PITER cohort 1.360
Premature ovarian senescence and a high miscarriage rate impair fertility in women with HCV 1.353
Management of primary biliary cholangitis in the pre-obeticholic acid era, and the rate of non-response to ursodeoxycholic acid (UDCA), in a large real-world cohort of PBC patients in Italy: The CLEO-AIGO database 1.308
Evaluation of antibody response to BNT162b2 mRNA COVID-19 vaccine in patients affected by immune-mediated inflammatory diseases up to 5 months after vaccination 1.297
Evolution of the HCV quasispecies and pattern of response to interferon therapy in patients with chronic hepatitis C 1.294
Real-world data on the treatment of primary biliary cholangitis with obeticholic acid in Italy: the CLEO-AIGO OCA cohort. 1.286
Optimization of hepatitis C virus screening strategies by birth cohort in Italy 1.278
Rate of non-response to ursodeoxycholic acid in a large real-world cohort of primary biliary cholangitis patients in Italy 1.271
Can antiretroviral therapy modify the clinical course of HDV infection in HIV positive patients? 1.256
Neutralizing Antibodies Responses against SARS-CoV-2 in a Sardinian Cohort Group Up to 9 Months after BNT162b2 Vaccination 1.239
null 1.208
La quasispecie del virus dell’epatite C: implicazioni biologiche e cliniche 1.202
Forecasting liver disease burden 1.184
A Protective HLA Extended Haplotype Outweighs the Major COVID-19 Risk Factor Inherited From Neanderthals in the Sardinian Population 1.182
Predictive Factors for Liver Disease Progression Following the Direct Acting Antivirals Induced Sustained Virological Response: Data from the Italian Platform for the Study of Viral Hepatitis Therapies (PITER) Cohort 1.172
Evaluation of HIV Transmission Clusters among Natives and Foreigners Living in Italy 1.116
Decrease in Incidence Rate of Hospitalizations Due to AIDS-Defining Conditions but Not to Non-AIDS Conditions in PLWHIV on cART in 2008-2018 in Italy 1.112
Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65 years with HCV genotype 1 cirrhosis 1.096
Advanced liver disease outcomes after hepatitis C eradication by human immunodeficiency virus infection in PITER cohort 1.091
Forecasting liver disease burden based on a real life cohort of the linked to care patients in Italy. Does the ‘underwater portion of the iceberg’ matter to reach the WHO HCV eliminating goals in the high HCV prevalent countries? 1.070
Risultati preliminari di uno studio di fase II con Sorafenib in pazienti anziani affetti da epatocarcinoma 1.055
Epidemiological and Economic Evaluations According to Daa Treatment Access in Italy Based on Real Life Piter Cohort Data 1.054
Multicenter prospective study of angiogenesis polymorphism validation in HCC patients treated with sorafenib. An Innovate study protocol 1.051
Long term effectiveness of DAA therapy in patients with chronic HCV and Mixed Cryoglobulinemic Syndrome 1.046
Optimization of Hepatitis C Virus screening strategies by birth cohort in Italy 1.035
A review of the main genetic factors influencing the course of COVID-19 in Sardinia: the role of human leukocyte antigen-G 1.031
Clinical characterization and economic impact evaluation of antiHCV DAA treatment failure:real life data from the Italian Platform for the Study of Viral Hepatitis Therapies (PITER) 1.029
Previous functional social and behavioral rhythms affect resilience to COVID-19-related stress among old adults 1.005
L'approccio basato sui casi per la diagnosi di malattie epatiche 1.002
Forecasting Hepatitis C liver disease burden based on real life data. Does the hidden iceberg matter to reach the World Health Organization elimination goals? 995
Mixed cryoglobulinemia: an important but frequently unrecognized and underestimated HCV-related condition in the real life practice 986
Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study 976
Distribution of IL28B polymorphism in a cohort of Italians and immigrants with HCV infection: association with viraemia, stage of fibrosis and response to treatment 963
Solid Organ Transplantation During COVID-19 Pandemic: An International Web-based Survey on Resources’ Allocation 939
Forecasting Hepatitis C liver disease burden on real life data. Does the hidden iceberg matter to reach the elimination goals? 937
Combined Salivary Proteome Profiling and Machine Learning Analysis Provides Insight into Molecular Signature for Autoimmune Liver Diseases Classification 927
STUDY OF VALIDATION OF ANGIOGENESIS POLYMORPHISMS IN HCC PATIENTS TREATEDWITH SORAFENIB. INNOVATE STUDY 917
L'Italia come modello per l'Europa e per il mondo nelle politiche sanitarie per il trattamento dell'epatite cronica da HCV Gruppo 913
Effectiveness and safety of glecaprevir/pibrentasvir in chronic hepatitis C patients: Results of the Italian cohort of a post-marketing observational study 912
Iron concentration and distribution in the newborn liver 883
Modeling cost-effectiveness and health gains of a “universal“ versus “prioritized“ hepatitis C virus treatment policy in a real-life cohort 875
Evaluation of Antibody Response to Heterologous Prime-Boost Vaccination with ChAdOx1 nCoV-19 and BNT162b2: An Observational Study 866
HCV-related mixed cryoglobulinemia: Data from PITER, a nationwide Italian HCV cohort study 863
The prevalence of bright liver echo pattern in patients with chronic hepatitis C: correlation with steatosis and fibrosis 863
Diagnostic and therapeutic approaches of mixed cryoglobulinemia in PITER (Piattaforma Italiana per lo studio della Terapia delle Epatiti viRali) cohort 860
Gender differences in HCV chronic liver disease: a reallife evaluation in PITER (PIATTAFORMA ITALIANA PER LO STUDIO DELLA TERAPIA DELLE EPATITI VIRALI) Cohort study. 858
COVID-19 Vaccine Hesitancy among Italian Healthcare Workers: Latent Profiles and Their Relationships to Predictors and Outcome 842
Totale 180.028
Salva come PNG Salva come JPEG
Categoria #
all - tutte 315.832
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 315.832
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202121.449 0 0 0 0 0 5.470 3.889 3.130 1.499 2.960 2.694 1.807
2021/202213.215 1.217 1.135 703 1.000 958 985 865 724 1.097 996 1.535 2.000
2022/202319.438 2.076 2.643 2.596 1.408 1.692 1.926 893 1.655 1.133 1.086 1.435 895
2023/202422.027 1.023 1.137 1.230 1.719 2.007 3.667 3.457 1.523 1.022 1.463 1.747 2.032
2024/202558.197 7.306 29.122 5.040 4.491 2.321 2.498 3.731 305 643 1.622 494 624
2025/20267.298 1.015 933 1.898 1.238 1.113 1.101 0 0 0 0 0 0
Totale 234.895